Provenge (sipuleucel-T) is an autologous cellular immunotherapy, which involves removing immune cells from a patient's blood, priming them to recognise prostate cancer, and then returning them to ...

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration ...

“The only therapeutic vaccine that's approved is Provenge (sipuleucel-T) which is a completely different mechanism so we don't know whether this particular oncolytic viral approach will have ...

Currently, only one personalized cancer vaccine has been approved by the Food and Drug Administration (FDA) for use in the United States: Provenge (sipuleucel-T) for prostate cancer. Specifically ...

The April 29 approval of Seattle-based Dendreon's prostate cancer vaccine, Provenge (sipuleucel-T), is being hailed as a victory for cancer immunotherapy. For Dendreon, the US Food and Drug ...

It’s been 13 years since the FDA approved its first therapeutic vaccine – Dendreon Pharma’s Provenge (sipuleucel-T) for prostate cancer, which was not a commercial success – and since then ...

sipuleucel-T, cabazitaxel, abiraterone, Provenge, Jevtana, and Zytiga. Reference citations from publications identified were also reviewed. Study Selection and Data Extraction: Articles identified ...

With the autologous DC vaccine Provenge (Sipuleucel-T), there was a trend toward increased OS in prostate cancer. All participants developed T-cell responses and half of the patients developed ...